Skip to main content

Month: March 2023

Dorel Reports Fourth Quarter and 2022 Year-End Results

Lower U.S. sales the main cause of lower earnings in both segments  Dorel Juvenile revenues increase in other markets Cost environment continuing to improveMONTREAL, March 13, 2023 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced results for the fourth quarter and year ended December 30, 2022.   Fourth quarter revenue from continuing operations was US$340.3 million, down 21.8%, from US$435.3 million a year ago. Reported net loss from continuing operations for the quarter was US$41.4 million or US$1.27 per diluted share compared to US$29.6 million or US$0.91 per diluted share a year ago. Adjusted net loss1 from continuing operations was US$39.8 million or US$1.22 per diluted share compared to US$12.0 million or US$0.37 per diluted share in the fourth quarter a year ago.   Revenue for the full year...

Continue reading

Westport Reports Fourth Quarter and Full Year 2022 Results

VANCOUVER, British Columbia, March 13, 2023 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport”) (TSX:WPRT / Nasdaq:WPRT) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on operations. All figures are in U.S. dollars unless otherwise stated. HighlightsRevenue of $305.7 million for 2022 and $78.0 million for the fourth quarter, down slightly over comparable periods in 2021 due to the weakening of the Euro against the U.S dollar. Net loss of $(32.7) million or $(0.19) per share, compared to net income of $13.7 million in the prior year. For the fourth quarter 2022 net loss was $(16.9) million. Adjusted EBITDA1 of $(27.8) million, compared to $17.5 million in the prior year. Adjusted EBITDA for the fourth quarter was $(12.9) million. Cash and cash equivalents...

Continue reading

AMREP Reports Third Quarter Fiscal 2023 Results

HAVERTOWN, Pa., March 13, 2023 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $16,574,000, or $3.12 per diluted share, for its 2023 fiscal third quarter ended January 31, 2023 compared to net income of $910,000, or $0.12 per diluted share, for the same period of the prior year. For the first nine months of 2023, AMREP had net income of $22,107,000, or $4.17 per diluted share, compared to net income of $5,873,000, or $0.80 per diluted share, for the same period of 2022. Revenues were $9,117,000 and $35,975,000 for the third quarter and first nine months of 2023 and $9,391,000 and $35,404,000 for the third quarter and first nine months of 2022. During the third quarter of 2023, AMREP recognized a non-cash pre-tax pension settlement expense of $2,336,000 as a result of its defined benefit pension plan...

Continue reading

One Liberty Properties Reports Fourth Quarter and Full Year 2022 Results

– Leased over 1.1 Million Square Feet in 2022 – – Occupancy At 99.8% – GREAT NECK, N.Y., March 13, 2023 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP), a real estate investment trust focused on net leased properties, today announced operating results for the quarter and year ended December 31, 2022. “We are excited that we delivered per share net income and AFFO growth as we continue our efforts to produce increasing value over time,” commented Patrick J. Callan, Jr., One Liberty Properties President and Chief Executive. “Revenues and AFFO grew in the fourth quarter and all of 2022, as we effectively navigated the challenging economic backdrop of rising inflation coupled with volatility in interest rates and financial markets. We expect to maintain our disciplined underwriting approach as we seek to acquire and dispose...

Continue reading

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and initiated Galatea Phase 2a trial evaluating TP-04 for Rosacea Cash runway anticipated into at least 2H 2026 to support planned TP-03 commercialization and continued pipeline development IRVINE, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2022, and recent business achievements. “In 2022 we had a...

Continue reading

Getty Images Reports Fourth Quarter and Full Year 2022 Results

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the fourth quarter and full year ended December 31, 2022. Craig Peters, Chief Executive Officer of Getty Images said, “Today marks Getty Images’ 28th anniversary. Over those 28 years, Getty Images has focused on producing and providing high quality, exclusive and authentic content that is born from our unique expertise, creativity and partnerships. This continues to be the heart of our business and focus. While we continue to see macroeconomic headwinds and foreign exchange impacts, Getty Images produced solid operational performance over 2022 and the fourth quarter. In spite of FX pressures, which impacted our reported revenue, we...

Continue reading

Oportun Reports Fourth Quarter and Full Year 2022

4Q22 Aggregate Originations of $610 million, bringing FY22 to $2.9 billion, up 27% 4Q22 Total revenue of $262 million, bringing FY22 to $953 million, up 52% 2023 cost actions enacted to save $48 to 53 million in annualized expensesSAN CARLOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Oportun Financial Corporation (Nasdaq: OPRT) (“Oportun”, or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022. “The fourth quarter exemplified the resilience of Oportun and our business model amidst a difficult macroeconomic backdrop. I’m pleased that we delivered a profitable quarter on an adjusted basis, despite the rising rate environment and the impact of inflation,” said Raul Vazquez, CEO of Oportun. “We grew our average daily principal balance sequentially...

Continue reading

GitLab Reports Fourth Quarter and Full Year 2023 Financial Results

Quarterly revenue of $122.9 million, up 58% year-over-year Fiscal Fourth Quarter Highlights:Total revenue of $122.9 million GAAP operating margin of (38)%; Non-GAAP operating margin of (11)% GAAP net loss per share of $(0.26); Non-GAAP net loss per share of $(0.03)Fiscal Year 2023 Highlights:Total revenue of $424.3 million GAAP operating margin of (50)%; Non-GAAP operating margin of (21)% GAAP net loss per share of $(1.16); Non-GAAP net loss per share of $(0.46)SAN FRANCISCO, March 13, 2023 (GLOBE NEWSWIRE) — All-Remote – GitLab Inc. (NASDAQ: GTLB), The DevSecOps Platform, today reported financial results for its fourth quarter and full fiscal year of 2023, ended January 31, 2023. “Now more than ever, it is critical for companies to show an immediate return on their software investments,” said Sid Sijbrandij, co-founder...

Continue reading

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments

— Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter — — Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26% Year-Over-Year — — Mammalian Cell Manufacturing is Now Online and Process Development Facility Expansions to be Online by End of Calendar Q1 2023, Adding Approximately $120 Million of Revenue Capacity — — Cell and Gene Therapy Facility Expansion Expected to be Online by End of Calendar Q3 2023 — — Reaffirming FY 2023 Revenue Guidance of Between $145 Million and $150 Million — TUSTIN, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

Continue reading

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023 Completed initial enrollment into the fourth dose level in the dose escalation part of the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors Data from the complete dose escalation part of the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors expected in 2023 Received orphan drug designation (ODD) from the European Commission for Nana-val for the treatment of diffuse large B-cell lymphoma; sixth ODD globally and the second in Europe Cash, cash equivalents and investments of $91.0 million as of December 31, 2022; anticipated cash runway into late 2024 SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) — Viracta...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.